Verastem Inc. (VSTM)

3.46
NASDAQ : Health Technology
Prev Close 3.38
Day Low/High 3.26 / 3.48
52 Wk Low/High 2.77 / 10.35
Avg Volume 2.20M
Exchange NASDAQ
Shares Outstanding 73.79M
Market Cap 249.41M
EPS -1.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Verastem Oncology To Present At The 37th Annual J.P. Morgan Healthcare Conference

Verastem Oncology To Present At The 37th Annual J.P. Morgan Healthcare Conference

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the Company will present at the 37 th Annual J.

Verastem Oncology Added To The NASDAQ Biotechnology Index®

Verastem Oncology Added To The NASDAQ Biotechnology Index®

Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that it has been selected for...

Verastem Oncology Announces First Recipient Of The Care Differently Award For Excellence In Patient Support And Education

Verastem Oncology Announces First Recipient Of The Care Differently Award For Excellence In Patient Support And Education

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, awarded the first annual Care Differently...

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of options to purchase 83,978 shares of its...

Verastem Oncology Presents Duvelisib Development Program Data At The American Society Of Hematology 2018 Annual Meeting

Verastem Oncology Presents Duvelisib Development Program Data At The American Society Of Hematology 2018 Annual Meeting

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the presentation of seven posters highlighting new and...

Verastem Oncology Announces Presentation Of Updated Duvelisib Combination Clinical Data In Peripheral T-Cell Lymphoma At The American Society Of Hematology 2018 Annual Meeting

Verastem Oncology Announces Presentation Of Updated Duvelisib Combination Clinical Data In Peripheral T-Cell Lymphoma At The American Society Of Hematology 2018 Annual Meeting

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced an oral presentation highlighting new clinical data from...

First Week Of VSTM January 2019 Options Trading

First Week Of VSTM January 2019 Options Trading

Investors in Verastem Inc saw new options begin trading this week, for the January 2019 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VSTM options chain for the new January 2019 contracts and identified the following put contract of particular interest.

VSTM: Insiders Vs. Shorts

VSTM: Insiders Vs. Shorts

The most recent short interest data was recently released for the 10/31/2018 settlement date, and Verastem Inc is one of the most shorted stocks of the Russell 3000, based on 7.68 "days to cover" versus the median component at 4.44. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Verastem Oncology Reports Third Quarter 2018 Financial Results

Verastem Oncology Reports Third Quarter 2018 Financial Results

Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today reported financial results for the third quarter ended September...

Verastem Oncology Announces Collaboration With The Leukemia & Lymphoma Society To Accelerate Development Of Duvelisib For The Treatment Of Peripheral T-Cell Lymphoma

Verastem Oncology Announces Collaboration With The Leukemia & Lymphoma Society To Accelerate Development Of Duvelisib For The Treatment Of Peripheral T-Cell Lymphoma

Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced a collaboration with The Leukemia & Lymphoma Society®...

Verastem Oncology Announces Presentation Of Preclinical Data Supporting Dual PI3K-delta And PI3K-gamma Inhibition In Combination With Immunotherapy At The Society For Immunotherapy Of Cancer's 33rd Annual Meeting

Verastem Oncology Announces Presentation Of Preclinical Data Supporting Dual PI3K-delta And PI3K-gamma Inhibition In Combination With Immunotherapy At The Society For Immunotherapy Of Cancer's 33rd Annual Meeting

Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced a poster presentation of preclinical data by Jonathan...

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of options to purchase 6,153 shares of its...

Verastem Enters Oversold Territory (VSTM)

Verastem Enters Oversold Territory (VSTM)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Verastem Oncology Announces Data Presentations At The American Society Of Hematology 2018 Annual Meeting

Verastem Oncology Announces Data Presentations At The American Society Of Hematology 2018 Annual Meeting

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that eight abstracts have been selected for presentation,...

The Power of Personalization: Cramer's 'Mad Money' Recap (Thursday 9/27/18)

The Power of Personalization: Cramer's 'Mad Money' Recap (Thursday 9/27/18)

Jim Cramer says you need to understand the theme behind the market's action, but also you need to know the timing.

Ferrari, Paychex, First American: 'Mad Money' Lightning Round

Ferrari, Paychex, First American: 'Mad Money' Lightning Round

Jim Cramer weighs in on Ferrari, Paychex, First American, Verastem, Halliburton and more.

Verastem Oncology Announces Executive Leadership Appointments And Changes

Verastem Oncology Announces Executive Leadership Appointments And Changes

Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the appointment of Ironwood Pharmaceuticals, Inc.

Verastem (VSTM) Shares Cross Below 200 DMA

Verastem (VSTM) Shares Cross Below 200 DMA

In trading on Friday, shares of Verastem Inc crossed below their 200 day moving average of $5.57, changing hands as low as $5.38 per share. Verastem Inc shares are currently trading down about 10.8% on the day.

Verastem Becomes Oversold (VSTM)

Verastem Becomes Oversold (VSTM)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Verastem Oncology Announces Pricing Of Registered Direct Offering Of $150 Million Of Convertible Notes

Verastem Oncology Announces Pricing Of Registered Direct Offering Of $150 Million Of Convertible Notes

Verastem, Inc., (Nasdaq: VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the pricing of an offering of 5.

National Comprehensive Cancer Network® Adds Verastem Oncology's COPIKTRA™ (duvelisib) Capsules To Clinical Practice Guidelines In Oncology For Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

National Comprehensive Cancer Network® Adds Verastem Oncology's COPIKTRA™ (duvelisib) Capsules To Clinical Practice Guidelines In Oncology For Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the National Comprehensive Cancer Network® (NCCN®)...

National Comprehensive Cancer Network® Adds Verastem Oncology's COPIKTRA™ (duvelisib) Capsules To Clinical Practice Guidelines In Oncology

National Comprehensive Cancer Network® Adds Verastem Oncology's COPIKTRA™ (duvelisib) Capsules To Clinical Practice Guidelines In Oncology

Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the National Comprehensive Cancer Network® (NCCN®)...

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of stock options to six new employees to...

Verastem Oncology Announces Publication Of The Phase 3 DUO Study Results In The Journal Blood

Verastem Oncology Announces Publication Of The Phase 3 DUO Study Results In The Journal Blood

Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the results of the Phase 3 DUO™ study, which...

IBM Is Among These 8 Stocks Set to Reverse Direction

IBM Is Among These 8 Stocks Set to Reverse Direction

These names are showing technical signs of either bullish or bearish reversal patterns over the past week.

Verastem Could Be Purchased After a Test of the 200-Day Average Line

Verastem Could Be Purchased After a Test of the 200-Day Average Line

Verastem could be a buy after a test of the 200-day line around $5.50.

Verastem Oncology To Present At Upcoming Investor Conferences

Verastem Oncology To Present At Upcoming Investor Conferences

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the Company will present at the following upcoming...

Interesting VSTM Put And Call Options For November 16th

Interesting VSTM Put And Call Options For November 16th

Investors in Verastem Inc saw new options begin trading this week, for the November 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VSTM options chain for the new November 16th contracts and identified one put and one call contract of particular interest.